ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Adjuvant Treatment Shapes the Bone Marrow Myeloid Compartment Towards an Immunosuppressive Phenotype That Can Suppress Allograft Rejection

J. Ge1, E. Anderson1, J. F. Markmann2, A. Cuenca1

1Surgery, Boston Children's Hospital, Boston, MA, 2Surgery, Massachusetts General Hospital, Boston, MA

Meeting: 2021 American Transplant Congress

Abstract number: 551

Keywords: Immunosuppression, Inflammation, Neutrophils, Vaccination

Topic: Basic Science » Innate Immunity; Chemokines, Cytokines, Complement

Session Information

Session Name: Innate Immunity; Chemokines, Cytokines, Complement

Session Type: Poster Abstract

Session Date & Time: None. Available on demand.

Location: Virtual

*Purpose: Myeloid derived suppressor cells (MDSCs) expand in response to inflammatory stimuli and have been shown to suppress adaptive immunity. Preliminary data from our lab suggests that adjuvant treatment expands MDSCs that can suppress allograft rejection. We hypothesized that distinct phenotypic and functional changes occur in bone marrow myeloid compartment that lead to the production of MDSCs following adjuvant treatment.

*Methods: C57Bl/6 mice were injected with 200 μl saline or alum intraperitoneally every other day for a total of 3 doses. Spleen, peripheral blood and bone marrow was examined at different time points via flow cytometry from either saline or alum treated mice. A separate aliquot of cells were stimulated with PMA (50 ng/mL) and ionomycin (1 ug/mL) and analyzed for the presence of IL-10 via flow cytometry.

*Results: At 7 days post adjuvant treatment, we noted an expansion of common myeloid progenitors (0.28 ± 0.044% vs 0.108 ± 0.013%, p=0.009), macrophage and DC progenitors (0.053 ± 0.010% vs 0.023 ± 0.003%, p=0.034) and common monocyte progenitors (0.62 ± 0.080% vs 0.39 ± 0.033%, p=0.038) in the bone marrow compared to saline controls. In alum treated animals, both monocytic (m)-MDSCs and granulocytic (g)-MDSCs significantly expanded in bone marrow, spleen, and peripheral blood and demonstrated significantly lower expression of CX3CR1 but increased expression of PD-L1, suggestive of a more suppressive phenotype. To support this, alum treatment increased IL-10 production by both M-MDSCs (34.37 ± 4.26 vs 11.32 ± 2.18%, p=0.028) and G-MDSCs (28.6 ± 2.54 vs 5.88 ± 1.46 %, p=0.007) in response to PMA stimulation compared to saline controls

*Conclusions: Adjuvant treatment skews the bone marrow myeloid compartment towards a potent suppressor phenotype. These data support our previous findings that adjuvant treatment can expand m-MDSCs and g-MDSCs that suppress adaptive immunity and allograft rejection. Our data suggest that adjuvants can be designed to selectively expand suppressor cell populations in vivo by shaping the bone marrow compartment. Further, this strategy could be utilized to condition transplant recipient preoperatively and decrease the significant morbidity associated with current immunosuppressive regimens.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ge J, Anderson E, Markmann JF, Cuenca A. Adjuvant Treatment Shapes the Bone Marrow Myeloid Compartment Towards an Immunosuppressive Phenotype That Can Suppress Allograft Rejection [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/adjuvant-treatment-shapes-the-bone-marrow-myeloid-compartment-towards-an-immunosuppressive-phenotype-that-can-suppress-allograft-rejection/. Accessed May 9, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences